JP5346216B2 - 治療 - Google Patents

治療 Download PDF

Info

Publication number
JP5346216B2
JP5346216B2 JP2008557821A JP2008557821A JP5346216B2 JP 5346216 B2 JP5346216 B2 JP 5346216B2 JP 2008557821 A JP2008557821 A JP 2008557821A JP 2008557821 A JP2008557821 A JP 2008557821A JP 5346216 B2 JP5346216 B2 JP 5346216B2
Authority
JP
Japan
Prior art keywords
polypeptide
tsg
seq
opg
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008557821A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009532334A (ja
JP2009532334A5 (enExample
Inventor
サボクバー，アフシー
デイ，アンソニー
ミルナー，カロリン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Manchester
Original Assignee
University of Manchester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Manchester filed Critical University of Manchester
Publication of JP2009532334A publication Critical patent/JP2009532334A/ja
Publication of JP2009532334A5 publication Critical patent/JP2009532334A5/ja
Application granted granted Critical
Publication of JP5346216B2 publication Critical patent/JP5346216B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2008557821A 2006-03-06 2007-03-06 治療 Expired - Fee Related JP5346216B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0604460.6A GB0604460D0 (en) 2006-03-06 2006-03-06 Treatment
GB0604460.6 2006-03-06
PCT/GB2007/000772 WO2007101988A2 (en) 2006-03-06 2007-03-06 Use of tsg-6 for treating bone diseases

Publications (3)

Publication Number Publication Date
JP2009532334A JP2009532334A (ja) 2009-09-10
JP2009532334A5 JP2009532334A5 (enExample) 2010-05-20
JP5346216B2 true JP5346216B2 (ja) 2013-11-20

Family

ID=36219200

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008557821A Expired - Fee Related JP5346216B2 (ja) 2006-03-06 2007-03-06 治療

Country Status (7)

Country Link
US (1) US9066908B2 (enExample)
EP (1) EP2001499B1 (enExample)
JP (1) JP5346216B2 (enExample)
DK (1) DK2001499T3 (enExample)
ES (1) ES2426196T3 (enExample)
GB (1) GB0604460D0 (enExample)
WO (1) WO2007101988A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8609334B2 (en) 2008-05-29 2013-12-17 The Regents Of The University Of California Biomarkers for painful intervertebral discs and methods of use thereof
WO2015094846A2 (en) * 2013-12-18 2015-06-25 The Texas A&M University System Treatment of gum diseases and gum disorders with tsg-6 protein
GB201910645D0 (en) * 2019-07-25 2019-09-11 Univ Manchester Treatment for dry eye disease
CN111273029B (zh) * 2020-02-25 2023-03-31 芜湖天明生物技术有限公司 rhTSG-6双抗体夹心ELISA法定量检测试剂盒及其使用方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
ATE185573T1 (de) 1991-01-14 1999-10-15 Univ New York Cytokin-induziertes protein, tsg-6, seine dna und verwendung
EP0705842A2 (en) 1994-10-06 1996-04-10 Hoechst Aktiengesellschaft Regulated genes by stimulation of chondrocytes with 1L-1beta
WO1997004075A1 (en) * 1995-07-20 1997-02-06 New York University Pharmaceutical compositions containing tsg-6 for treating inflammatory diseases and cancer-related pathologies and methods
WO1999007891A1 (en) * 1997-08-05 1999-02-18 Human Genome Sciences, Inc. 90 human secreted proteins
AU2002253133B2 (en) * 2001-04-03 2008-02-28 Societe Des Produits Nestle S.A. Osteoprotegerin in milk
ITRM20030595A1 (it) 2003-12-23 2005-06-24 Sigma Tau Ind Farmaceuti Uso della ptx3 o di un suo derivato funzionale da sola o in associazione con tsg6 per il trattamento di patologie degenarative dell'osso o della cartilagine e per il trattamento della infertilita' femminile.

Also Published As

Publication number Publication date
WO2007101988A2 (en) 2007-09-13
ES2426196T3 (es) 2013-10-21
US9066908B2 (en) 2015-06-30
JP2009532334A (ja) 2009-09-10
DK2001499T3 (da) 2013-09-08
US20090099084A1 (en) 2009-04-16
EP2001499A2 (en) 2008-12-17
GB0604460D0 (en) 2006-04-12
WO2007101988A3 (en) 2007-11-01
EP2001499B1 (en) 2013-06-05

Similar Documents

Publication Publication Date Title
JP5822822B2 (ja) Ｔｎｆファミリー受容体を標的とし、ｔｎｆ作用を拮抗するペプチド、その組成物、方法および使用
Wang et al. Extracellular role of HMGB1 in inflammation and sepsis
EP2892547B1 (en) A dominant negative tnf-alpha inhibitor for use in treating neurological disorders of the cns
AU2006256891B2 (en) Use of the ideS proteinase (from s. pyogenes) for treating autoimmune diseases and graft rejection
KR20020084842A (ko) Ｂａｆｆ 수용체(ｂｃｍａ), 면역조절제
US20030171253A1 (en) Methods and compositions relating to modulation of A20
US9403891B2 (en) Methods and compositions for modulating TNF/TNFR signaling
CN110420331B (zh) Alkbh5抑制物在治疗病毒感染性疾病中的应用
US9878003B2 (en) Method of treating bone disorders using TSG-6
US20150139999A1 (en) Interferon antagonists, antibodies thereto, and associated methods of use
JP5346216B2 (ja) 治療
BG66137B1 (bg) Хемокинови мутанти за лечение на мултиплена склероза
JP2007517021A (ja) 長いペントラキシンｐｔｘ３の阻害剤を含む医薬
JPWO1999014325A1 (ja) 新規Ｆａｓリガンド誘導体
KR20190131068A (ko) 인간화된 항-cxcr5 항체를 사용하는 루푸스의 치료
WO2022056493A1 (en) Biomarker driven methods for treating major depressive disorder
JP2005529099A (ja) 改善された経口生物学的利用能を有するケモカイン変異体
WO2025015103A1 (en) Methods for modulating activity of il-18 for treatment of cd4+ t cell mediated autoimmunity and immunopathology
Fisher Experimental therapies in primary Sjögren's syndrome
WO2019038420A1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF OSTEOCLAST DISEASES
HK1101500A (en) Medicament comprising inhibitors of long pentraxin ptx3

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20100227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100303

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100329

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120612

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120912

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120920

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121004

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121012

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121112

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20121214

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130219

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20130220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130619

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20130704

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130723

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130816

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 5346216

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees